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Abstract MPS encompasses a group of rare lysosomal stor-
age disorders that are associated with the accumulation of
glycosaminoglycans (GAG) in organs and tissues. This accu-
mulation can lead to the progressive development of a variety
of clinical manifestations. Ear, nose, throat (ENT) and
respiratory problems are very common in patients with MPS
and are often among the first symptoms to appear. Typical
features of MPS include upper and lower airway obstruction
and restrictive pulmonary disease, which can lead to chronic
rhinosinusitis or chronic ear infections, recurrent upper and
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lower respiratory tract infections, obstructive sleep apnoea,
impaired exercise tolerance, and respiratory failure. This re-
view provides a detailed overview of the ENT and respiratory
manifestations that can occur in patients with MPS and dis-
cusses the issues related to their evaluation and management.
MPS disease overview
The mucopolysaccharidoses (MPS) are rare inherited meta-
bolic diseases associated with deficiencies in enzymes in-
volved in the degradation of glycosaminoglycans (GAG)
(Muenzer 2011). Progressive accumulation of GAG in multi-
ple tissues and organs (Table 1) lead to an array of manifes-
tations that worsen with age, ultimately resulting in severe
morbidity and premature death (Muenzer 2011).Most patients
share a typical appearance characterized by coarsened facial
features, reduced height, and skeletal abnormalities. Other
manifestations include impaired vision and hearing, hepa-
tosplenomegaly, cardiovascular disease, spinal cord compres-
sion, and ear-nose-throat (ENT) and respiratory problems.
Cognitive impairment is the main feature in MPS III and may
occur in MPS I, II and VII. Although many similarities exist,
the spectrum and severity of disease manifestations vary
between and within the different MPS types.
This review addresses ENTand respiratory disorders occur-
ring in MPS, and discusses their evaluation and management.
Physiology of respiration and impact of sleep
Respiration results from the interaction of pathways under
cerebral control. The brain controls the synchronous move-
ment of the diaphragm, ribs and abdomen; modulating
influences are exerted by feedback from arterial blood gas
tensions, pH and pulmonary-mechanical factors. The brain
also controls phasic coordination of upper airway (UA)
muscles, which interact with anatomic factors to determine
the UA resistance. Coordinated activity of the chest wall and
UA muscles is required to achieve normal ventilation.
Changes in UA and diaphragmatic control occur with sleep
onset, and can thus disrupt ventilation.
ENT and respiratory disorders in MPS
Respiratory disorders occur in all MPS types (John et al
2011; Leighton et al 2001; Lin et al 2010; Muhlebach et al
2011; Nashed et al 2009; Santamaria et al 2007; Semenza
and Pyeritz 1988) (Table 2). However, due to low patient
numbers no conclusions can be made regarding the preva-
lence and severity of these problems in each MPS type. The
ENT and respiratory disorders can be divided into airway
abnormalities, alterations in respiratory mechanics, and
effects of sleep (Fig. 1 and Table 3).
Airway abnormalities
Supraglottic manifestations are common in MPS and develop
due to cranial and spinal abnormalities (e.g., flattened nasal
bridge, short neck, high epiglottis, mandibular abnormalities,
abnormal cervical vertebrae) and GAG deposition in the
mouth, nose and throat (Leboulanger et al 2011; Leighton et
al 2001; Myer 1991; Shih et al 2002). Oral manifestations
include gingival hyperplasia, mucosal oedema, mucoid secre-
tions, and impaired opening of the mouth. Chronic rhinosinu-
sitis and chronic otitis media may occur and produce hearing
impairment (John et al 2011; Muhlebach et al 2011), and the
rhinosinusitis can contribute to UA obstruction during sleep.
GAG storage can also cause distension of the tongue,
adenoids and/or tonsils with formation of collapsible, space-
occupying lesions in pharyngolaryngeal walls (Simmons et al
2005). In extreme cases, excessive tissue at the arytenoid
cartilages and aryepiglottic folds can prolapse into the laryn-
geal inlet causing stridor and airway compromise (Simmons et
al 2005). Obstruction is often worsened by presence of thick-
ened secretions throughout the upper and lower respiratory
tracts (Leighton et al 2001). ENT manifestations are among
the first disease-specific manifestations to appear, may trigger
diagnosis of MPS (Muhlebach et al 2011; Wold et al 2010),
and tend to progress with age.
Table 1 Overview of types of
mucopolysaccharidosis (MPS)
and glycosaminoglycans that










I (H, HS, S) Hurler, Hurler-Scheie, Scheie + +
II Hunter + +
III Sanfilippo +
IVa Morquio + +
IVb +
VI Maroteaux-Lamy + +
VII Sly + + +
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Airway abnormalities and airway collapse may also occur
in infraglottic airways, including the trachea and central air-
ways. Tracheobronchomalacia may develop secondary to
GAG deposition in the tracheobronchial cartilage (Nagano et
al 2007; Pelley et al 2007; Shih et al 2002; Sims and
Kempiners 2007). Alternatively, tracheal collapse can occur
due to decreased tracheal traction from decreased lung volume
(Heinzer et al 2005), although this has not been specifically
shown in MPS. MPS IV patients may develop airway occlu-
sion upon neck flexion. These patients assume a “sniff posi-
tion” (extension of the neck to increase airway patency)
during wakefulness and may sleep in the prone position.
Clinical manifestations include dyspnoea, difficulty clearing
secretions, cough, wheezing, and recurrent bronchitis or pneu-
monia (John et al 2011; Leighton et al 2001; Muhlebach et al
2011; Murgu and Colt 2006; Pelley et al 2007). Another study
also suggested alveolar and interstitial pulmonary involve-
ment by GAG deposition (Semenza and Pyeritz 1988). Air-
way obstruction and parenchymal abnormality have potential
to impair pulmonary O2 uptake and CO2 excretion.
Alteration in respiratory mechanics
Multiple abnormalities in MPS patients can reduce ventilatory
capacity, manifesting as reduction in vital capacity (VC).
Kyphoscoliosis and pectus carinatum are common and alter
chest wall shape and structure. Diaphragm excursion may be
compromised by liver and spleen enlargement (Buhain et al
1975; Giugliani et al 2007; Leighton et al 2001). Diaphrag-
matic weakness may result from spinal cord compression
above the phrenic nerve origin (C3-C5), but there is currently
no evidence for this hypothesis.
Pulmonary function can also be affected by the characteris-
tic short stature and skeletal dysplasia. In MPS disorders
associated with short stature (e.g., MPS VI), patient height is
the primary determinant of VC and improved pulmonary
function during enzyme replacement therapy (ERT) is fre-
quently associated with growth and increased stature (Swiedler
et al 2005; Harmatz et al 2010).
The combined effect of these alterations in respiratory
mechanics coupled with airway abnormalities may lead to
respiratory failure.
Effects of sleep
Ventilatory compromise is exacerbated by normal sleep mech-
anisms that increase UA collapsibility, thus magnifying any
impairment to generation of inspiratory effort. The effects of
sleep are particularly evident during REM sleep, which causes
loss of tone in accessory muscles of respiration and reduction
in ventilatory CO2 chemosensitivity (Dempsey et al 2010).
Due to the changes that occur with sleep onset, ventilatory
compromise often first manifests as sleep disordered breathing
(SDB) and unexplained hypoxemia during sleep.
Table 2 Key respiratory manifestations in the different mucopolysac-
charidosis (MPS) types. Adapted from Muhlebach et al 2011, with







I +++ +++ +++
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VI +++ +++ ++
VII +++ +++ ++
Airway Obstruction
Narrowing of supraglottic
and infraglottic airway due to 
• GAG deposition and 
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• abnormalities of trachea 
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Fig. 1 Mechanisms that
predispose to sleep disordered
breathing in patients with
mucopolysaccharidosis (MPS)
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SDB occurs in >80 % of MPS patients (John et al 2011;
Leighton et al 2001; Semenza and Pyeritz 1988). It can be
categorized as either obstructive sleep apnoea (OSA) or
sustained hypoventilation. OSA occurs from an interaction
between abnormalities of the skull and GAG deposition in
the UA and perhaps from remote effects of thoracic defor-
mation causing reduced lung volumes. OSA can lead to
daytime sleepiness and long-term cardiovascular sequellae
and often presents as loud and disruptive snoring. Sleep
studies demonstrate recurrent short episodes (<90 s) of
either reduced or absent ventilation due to UA obstruction.
In more advanced stages, compensation for CO2 retention
during individual SDB events may be impaired by reduction
of VC and inability to increase ventilation during inter-event
intervals (Fig. 2) (Berger et al 2000). These patients exhibit
progressive CO2 retention throughout the night, i.e., noctur-
nal hypoventilation (Mellies et al 2003; Ragette et al 2002).
A restrictive abnormality and/or diaphragmatic weakness
may also cause sustained periods of hypoventilation. Sleep
studies demonstrate prolonged periods (several minutes) of
arterial O2 desaturation consequent to hypoventilation
(Leighton et al 2001). Reduced VC, which is influenced
by respiratory muscle strength, may be a good predictor of
SDB severity (Ragette et al 2002). Whereas patients with
VC <60 % of predicted have a predisposition to SDB, those
with a VC <40 % of predicted are prone to sustained
hypoventilation and CO2 retention.
If improperly managed, nocturnal hypoventilation may lead
to pulmonary hypertension, cor pulmonale and eventually res-
piratory failure (John et al 2011; Semenza and Pyeritz 1988), a
common cause of death in MPS (Leighton et al 2001).
Other potential mechanisms
Tracheal distortion is characteristic for MPS and may reflect
disproportionate length of the trachea relative to the shortened
spinal length (Walker et al 2003). In combination with laxity
of tracheal tissue, it can cause airway collapse (Walker et al
2003). Cervical or lumbar spinal cord lesions may weaken
expiratory muscles, impair cough and reduce secretion clear-
ance, predisposing patients to recurrent pneumonia. In
patients with cardiac abnormalities or chronic respiratory fail-
ure, nocturnal shift in leg fluid volume may cause UA oede-
ma. Furthermore, the respiratory arousal threshold (i.e., the
ease with which an individual wakes up in response to respi-
ratory stimuli) may be modified due to brain modifications.
However, these issues remain to be investigated.
Assessment of respiratory function in MPS patients
Evaluation of UA anatomy
Classification systems for grading mouth and UA abnormal-
ities in MPS include a modified Mallampati classification
system based on visibility of the tonsils, pillars, uvula and
soft palate and a classification system for grading tonsillar
hypertrophy (Friedman et al 1999). Computed tomography
(CT) of retropalatal and retroglossal spaces can demonstrate
reduction in UA volume in MPS patients (Santamaria et al
2007). Multi-detector CT imaging can also evaluate airway
size, airway structure and the lung parenchyma (Ingelmo et
al 2011) (Fig. 3i and j).
Dynamic changes in the airway during respiration can be
evaluated using flexible endoscopy (Fig. 3a, b, c, d, e, f, g and
h). Fiberoptic examination is preferably done in a sitting posi-
tion, which requires less ventilatory support than the supine
position. Pharyngeal and laryngeal abnormalities can be classi-
fied based on the level of mucosal alteration (personal commu-
nication Dr. A. Keilmann). Grading systems based on adenoid
hypertrophy and obstruction of the choanal opening and tubal
ostium exist to evaluate nasal cavity obstruction (Cassano et al
2003; Josephson et al 2011; Parikh et al 2006).
Table 3 Manifestations of mucopolysaccharidosis (MPS) that may af-
fect respiratory function and their prevalence in a study including 21
patients with MPS I, II, IV, VI, and VII. Adapted from Semenza et al
(Semenza and Pyeritz 1988), with permission from Williams & Wilkins
% of patients (N021)
Airway narrowing










Arterial hypoxemia awake 57










Cervical spine subluxation 68
Odontoid hypoplasia 69
Cord compression 63
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Fig. 2 Impaired compensation
for sleep disordered breathing,
leading to hypoventilation
during sleep. Reproduced from
Berger et al (Berger et al 2000),







Fig. 3 a Oropharyngeal image from a patient withmucopolysaccharidosis
(MPS) II showing macroglossia and gingival hyperplasia; b normal lyar-
yngoscopic image; c-d laryngoscopic images from a patient with MPS II
showing a thick laryngeal wall, tonsillar hyperplasia, and redundant aryte-
noid mucosa prolapse into laryngeal inlet; e-f nasal endoscopic images
showing inflammation and abnormal mucous secretion in a patient with
MPS VI; g normal bronchoscopic image (Canani et al 2003); h-j broncho-
scopic image and CT scans from a patient with MPS IV showing tracheal
deformity and narrowing; k-l typical frontal and lateral plain X-rays of the
chest of a child with MPS II showing skeletal abnormalities and the
presence of a tracheostomy and possibly infective changes in the lungs
(hazy shadow in the right lower zone of the frontal image)
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Plain roentgenograms of the chest, spine and soft tissue of
the neck may demonstrate airway obstruction, atelectasis,
skeletal changes that cause restrictive disease and/or spinal
cord compression (Fig. 3k and l). Magnetic resonance imag-
ing may provide information on skeletal changes, but has
limited utility for evaluating lung parenchyma. Imaging
MPS patients can be challenging. Sedation may be required
for young or uncooperative patients, although complications
may occur due to the high anaesthetic risk (Walker et al 2012).
Assessment of respiratory function
Respiratory symptoms and hypoventilation may not be
detected as many patients are inactive and since respiratory
dysfunction is often poorly correlated with clinical appear-
ance. Nevertheless, anticipation of respiratory problems and
management at an early stage is important to maximize treat-
ment outcome. Symptoms that require evaluation include
progressive dyspnoea, reduced physical activity, exercise in-
tolerance, wheezing or stridor, tachycardia and cyanosis.
Spirometry is the most frequent test utilized in MPS to
assess the VC and the forced expiratory volume in 1 s
(FEV1). Reduction in VC is suggestive of a restrictive
abnormality while reduction in FEV1 (expressed as FEV1/
VC) indicates airflow obstruction. Reduction in VC can
reflect changes in lung compliance, chest wall compliance,
and/or neuromuscular weakness. Reduced VC may also
result from air trapping. Standard normal values for spirom-
etry cannot be applied in MPS patients due to the disease-
induced growth impairment and expressing VC as a % of
normal is of limited value (Swiedler et al 2005). In addition,
spirometry may not be possible in children who are too
young to cooperate (< 5 years) and in patients with cognitive
impairment. Despite its limitations, spirometry remains a
valid clinical tool since all respiratory abnormalities that
occur in MPS produce a decrease in VC. Spirometry has
been commonly used for screening, to determine longitudi-
nal disease progression and assess response to therapy.
Maximum voluntary ventilation (MVV) can be assessed as
an alternative to spirometry. However, this test is physically
demanding and can be difficult for MPS patients. Promising
alternatives to assess for airflow obstruction include multiple
breath inert gas washout and impulse oscillometry. These tests
are performed during tidal breathing and may detect early
airway disease (Aurora et al 2005; Oppenheimer et al 2007;
Pasker et al 1996; Klug and Bisgaard 1996; Hellinckx et al
1998).
The degree of pulmonary restriction or hyperinflation can be
measured using plethysmograhy, helium dilution or nitrogen
washout. The diagnosis and management of parenchymal dis-
ease requires measurement of diffusion. This measurement is
only reliable if the minimum volume inspired is 1.2 L and may
not be possible in MPS patients with reduced lung capacity.
Respiratory failure
Respiratory failure occurs from an imbalance between ventila-
tion and metabolic rate. It can be identified by presence of
hypercapnia on analysis of arterial blood gases. Since arterial
blood gas analysis may not be available in the outpatient clinic,
serum bicarbonate (HCO3
-) concentration serves as a screening
test since elevated values may indicate renal compensation for
respiratory acidosis. If the serum [HCO3
-] is ≥28 mEq/L, respi-
ratory failure should be suspected and assessment of arterial
blood gases should be considered (Mokhlesi et al 2007).
Sleep studies
Sleep studies/polysomnograpy are used to diagnose and
determine severity of respiratory sleep disorders. Since the
incidence of SDB is high in MPS, polysomnography should
be performed in all patients after diagnosis. Studies can be
repeated based on presence of snoring, excessive daytime
somnolence, development of respiratory failure and reduc-
tion in VC. Typical findings include recurrent OSA, tachy-
cardia, decrease in arterial O2 saturation and recurrent
arousal (Kamin 2008). It is important to distinguish OSA
from sustained hypoventilation as these require different
treatment approaches. Sustained nocturnal hypoventilation
is suggested by oxygen desaturation in absence of OSA and
can be confirmed by an increase in PCO2 during sleep, but
this often carries over into wakefulness.
Exercise tolerance testing
Exercise intolerance in MPS patients is generally measured
using timed stair climbing or walk tests (e.g., 6- and 12-min
walk tests [MWT]) (Harmatz et al 2008; Muenzer et al
2006; Wraith et al 2004). The 6-MWT is a practical test of
submaximal functional capacity which mimics daily activi-
ties (e.g., American Thoracic Society 2002). Timed walk
tests are used to assess functional status, monitor disease
progression and response to interventions. The distance
walked is generally the only variable that is evaluated.
Valuable additional information could be obtained by mea-
suring resting and end-exercise heart rate and arterial O2
saturation (e.g., American Thoracic Society 2002). Refer-
ence values for the 6-MWT exist (Enright and Sherrill 1998;
Li et al 2007); however, applicability in MPS is unclear due
to the associated cognitive and physical impediment.
Although not currently used, cardiopulmonary exercise
testing might be valuable because of its wider diagnostic
scope in terms of respiratory, cardio-circulatory and muscle-
metabolic function (American Thoracic Society/American
College of Chest Physicians 2003; Wasserman et al 2012).
The symptom-limited ramp test provides a gradational stress
spanning the entire tolerance range, with breath-by-breath
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measurement of ventilatory, gas-exchange and cardiovascu-
lar variables providing the substrate for analysing the causes
of exercise intolerance, based on profiles of physiological
system function.
Management of airway problems in MPS
Airway management
UA collapse at the pharyngeal and laryngeal level may
occur due to rhinitis or adenoidal obstruction. Treat-
ments may include nasal decongestions to control ex-
cessive mucus production, and steroids to reduce
swelling. Adenoidectomy and/or tonsillectomy are also
often required, and frequently performed before diagno-
sis of MPS. The procedure can be dangerous as sur-
geons may not anticipate potential anaesthetic and
surgical complications and procedures should be per-
formed by experienced personnel (Walker et al 2012;
Simmons et al 2005). The operative field is frequently
limited by thick and hard oropharyngeal tissue and UA
scar tissue that may compromise the already small air-
way (Yeung et al 2009). In advanced cases, andenoton-
sillectomy can be inadequate or impossible. Moreover,
any improvements achieved may be temporary because
of progressive involvement of the oropharynx and tra-
chea (Kamin 2008; Muhlebach et al 2011).
Patients with lower airway obstruction may use inhaled
steroids to decrease airway inflammation. Because of insta-
bility of the tracheal and bronchial wall, patients may re-
spond better to an anticholinergic bronchodilator agent than
to a beta-agonist (Muhlebach et al 2011).
SDB
The presence of SDB should prompt evaluation of the
UA. Removal of tonsils and adenoids, if enlarged, may
alleviate UA obstruction. SDB can also be managed by
application of continuous positive airways pressure
(CPAP), which delivers air at an elevated pressure using
a mask that fits around the nose +/− mouth (Sullivan et
al 1981; Rapoport et al 1982; Ginzburg et al 1990). The
pressure acts as a dynamic stent and prevents airway
collapse during inspiration. Nocturnal hypoventilation
should be suspected if arterial O2 desaturation persists
with CPAP or occurs in the absence of OSA (Berger et
al 2001). In this case, non-invasive ventilator support
systems (e.g., bilevel positive airway pressure) can be
utilized and a backup respiratory rate can be added to
prevent sustained hypoventilation. (Muhlebach et al
2011). Assisted ventilation may provide respiratory mus-
cle rest and improve sleep quality, relieve nocturnal
dyspnoea and lead to normalization of daytime blood
gases. Supplemental O2 can be added if arterial O2
desaturation persists but should be used with caution as
it may suppress ventilatory and arousal drives. Careful
titration of the rate of O2 administration and monitoring
of arterial CO2 levels are required to prevent O2-induced
hypercapnia.
As compliance with CPAP and non-invasive ventilation
is often low in MPS, compliance monitoring is imperative.
In addition, leaks due to poor-fitting masks reduce treatment
efficacy (Kamin 2008; Muhlebach et al 2011). Patients who
adopt a sniff position may require specialized attention to
ensure comfortable and adequate therapy. If properly used,
CPAP and bilevel devices will improve breathing during
sleep and provide relief of daytime somnolence and other
consequences of SDB.
Tracheostomy may be required either when CPAP or non-
invasive ventilation is ineffective or tracheomalacia and UA
obstruction are present during wakefulness (Muhlebach et al
2011; Wold et al 2010). However, placement of the trache-
ostomy tube can be difficult and may be associated with
stomal narrowing, granulation formation, infrastomal trache-
al stenosis, wound infection, and tracheomalacia (Jeong et al
2006; Muhlebach et al 2011; Pelley et al 2007; Sims and
Kempiners 2007). Problems may persist due to persistent
airway collapse distal to the tip of the endotracheal tube
(Pelley et al 2007) and patient preference for sleeping in
the prone position. When the above therapies are ineffective,
uncontrolled respiratory failure with cor pulmonale may
develop and death may occur.
Fig. 4 Changes from baseline in forced vital capacity (FVC) and forced
expiratory volume in 1 s (FEV1) after initiation of enzyme replacement
therapy (ERT). Results from a long-term extension study in patients with
mucopolysaccharidosis VI (Harmatz et al 2010), reproduced with per-
mission. n*: number of patients for whom data were available for that
particular time point
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Supportive therapies
Multiple supportive therapies are required to maintain
optimal functional status. All patients should receive reg-
ular vaccinations, including pneumococcus and influenza
vaccinations. Treatment of respiratory tract infections
should be early and aggressive. Impairment in secretion
clearance can be addressed by both manual and mechan-
ical techniques. Inhaled bronchodilators can be used in
conjunction with these airway clearance techniques. Bron-
chodilators and corticosteroids (inhaled and/or oral) may
be useful if concurrent asthma is present. As restrictive
pulmonary disease may be caused be spinal cord com-
pression, pulmonary function may also improve after de-
compression surgery.
Disease-targeting therapies
ERT is available for and beneficial in patients with MPS I,
II, and VI. A positive impact has been demonstrated on 6- or
12-MWT and on pulmonary function (Clarke et al 2009;
Harmatz et al 2004, 2005, 2006; Muenzer et al 2011, 2006;
Okuyama et al 2010; Wraith et al 2004).
An open-label extension study of ERT in MPS VI showed
sustained improvement in walking distance for up to
240 weeks (Harmatz et al 2008). In addition, FEV1 and VC
increased (11 % and 17 %, respectively) after 96 weeks of
ERTwith continued improvement thereafter (Fig. 4) (Harmatz
et al 2010). Sustained improvement in MVV has also been
demonstrated. These findings suggest that improved exercise
tolerance in this population was related, at least partly, to
improved pulmonary function.
The impact of ERT on pulmonary function should be
interpreted in relationship to patient age. In younger children,
increases in pulmonary function over time may (partly) be
explained by growth. In line with this consideration, improve-
ment in VC was only seen in patients with MPS II up to
18 years old (Muenzer et al 2011). In contrast, in MPS VI
patients, (Harmatz et al 2010) increases in VC and FEV1 were
observed in patients >12 years old despite minimal increases
in height. In these patients, improvement in pulmonary func-
tion could only be explained by mechanisms other than
growth, such as changes in bony structure, improvements in
mobility, joint contractures or respiratory muscle function,
shrinking of liver and spleen, or decreased GAG deposition
in soft tissues. In adolescent patients, changes in pulmonary
function may also be related to puberty.
Although haematopoietic stem cell transplantation
(HSCT) is beneficial, and superior to ERT, for prevention
of cognitive decline in young patients with MPS IH, effects
in other MPS types tend to be poor (Rovelli 2008). Its use has
been limited in the past by a high morbidity and mortality
rate and the lack of matched donors, but this is changing with
the increasing use of cord blood allowing a shorter interval
between diagnosis and HSCT and a lower graft failure rate
(Turbeville et al 2011; Prasad and Kurtzberg 2010). Most
knowledge on the effect of HSCT on pulmonary function is
based on case reports, some suggesting a positive impact
(Krivit et al 1984; Wang et al 2008).
Conclusions
The high prevalence of ENT and respiratory manifestations
in MPS patients, their severity, and their appearance early in
the disease course dictate that evaluation and follow-up of
these problems is extremely important. Since asymptomatic
patients may have severely impaired pulmonary function,
pulmonary disease may go undetected for years without
appropriate screening. However, the measurement of pul-
monary function in MPS patients remains an important
challenge due to the complexity of the disease and a lack
of data on “usual pulmonary function” in these patients.
Nevertheless, longitudinal follow-up of absolute values
can be useful for monitoring the evolution of respiratory
disease in a single patient. Current management guidelines
for MPS I and MPS VI therefore recommend pulmonary
function testing at diagnosis and every 6–12 months there-
after (Giugliani et al 2007; Muenzer et al 2009).
This review has addressed the pathophysiological mecha-
nisms underlying respiratory manifestations in the different
types of MPS. In addition, opportunities for enhanced evalua-
tion of pulmonary function in these patients were highlighted.
More sophisticated evaluation should help determine the mech-
anisms underlying the impact of ERT on exercise tolerance,
VC, and FEV1.
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